key: cord-0907841-pkr3immj authors: Staines, H. M.; Kirwan, D. E.; Clark, D. J.; Adams, E. R.; Augustin, Y.; Byrne, R. L.; Cocozza, M.; Cubas-Atienza, A. I.; Cuevas, L. E.; Cusinato, M.; Davies, B. M. O.; Davis, M.; Davis, P.; Duvoix, A.; Eckersley, N. M.; Edwards, T.; Fletcher, T.; Forton, D.; Fraser, A.; Garrod, G.; Hadcocks, L.; Hu, Q.; Johnson, M.; Kay, G. A.; Klekotko, K.; Lewis, Z.; Mensah-Kane, J.; Menzies, S.; Mason, J.; Monahan, I.; Moore, C.; Nebe-von-Caron, G.; Owen, S. I.; Sainter, C.; Sall, A. A.; Schouten, J.; Turtle, L.; Williams, C.; Wilkins, J.; Woolston, K.; Fitchett, J. R. A.; Krishna, S.; Planche, T. title: Dynamics of IgG seroconversion and pathophysiology of COVID-19 infections date: 2020-06-09 journal: nan DOI: 10.1101/2020.06.07.20124636 sha: 707632c5db82f859f996e2163a9334a6bebf42ce doc_id: 907841 cord_uid: pkr3immj We report dynamics of seroconversion to SARS-CoV-2 infections detected by IgG ELISA in 177 individuals diagnosed by RT-PCR. Longitudinal analysis identifies 2-7% of individuals who do not seroconvert even weeks after infection. They are younger and less severely affected than seroconverters. Higher antibody responses are associated with symptomatic disease, older age, ethnicity, increased co-morbidity and higher inflammatory markers such as C Reactive Protein. Antibody responses do not decline during follow up almost to 2 months. Serological assays increase understanding of disease severity. Their application in regular surveillance will clarify the duration and protective nature of humoral responses to SARS-CoV. ! 3! Introduction! SARSJCoVJ2!is!a!betacoronavirus!that!causes!Coronavirus!DiseaseJ19!(COVIDJ19),!an! acute!severe!respiratory!infection!with!systemic!involvement!and!an!estimated!case!fatality! rate!of!1% 1 .!COVIDJ19!was!first!documented!in!Wuhan!(Hubei!province)!China 2 !at!the!end!of! 2019!and!rapidly!transformed!from!a!localised!outbreak!to!a!global!pandemic.!Countries! have!tried!to!manage!the!pandemic!by!implementing!different!strategic!interventions!with! variable!success 3 .!All!agree!that!diagnostic!tests,!and!the!subsequent!interventions!they! unlock,!are!central!to!controlling!SARSJCoV2!transmission.!COVIDJ19!has!introduced! formidable!disruption!in!low!income!countries!where!diagnostic!tests!remain!unaffordable.! ! National!strategies!for!containment!are!severely!limited!by!availability!of!clinically!validated! diagnostic!tests.!The!urgent!scale!up!of!global!nucleic!acid!amplification!test!(RTJPCR)! capabilities!exposed!further!vulnerabilities!in!supply!chains!including!shortages!of!swabs!and! reagents!for!extraction!and!amplification!of!RNA.!!RTJPCR!became!available!soon!after! SARSJCoVJ2!was!sequenced!because!such!tests!do!not!need!production!of!viral!proteins 4 ! or!assay!development!that!relies!on!material!from!COVIDJ19!patients!and!those!who!have! never!been!infected.!! ! Serological!assays!for!viral!infections!can!contribute!to!all!aspects!of!their!containment! including!vaccine!development,!diagnostic!deployment,!and!prescription!of!novel! therapeutics.!They!may!also!clarify!pathophysiological!aspects!of!COVIDJ19.!We!have!used! an!enzymeJlinked!immunosorbent!assay!(ELISA,!Mologic!Ltd,!Bedford,!UK)!and!rapid! diagnostic!tests!(RDT)!for!COVIDJ19!developed!for!affordability!and!accuracy!so!that!they! can!be!accessible!and!can!be!manufactured!in!lowJ!and!middleJincome!countries!(LMICs).! We!describe!the!application!of!this!ELISA!to!serum!samples!obtained!from!a!cohort!of! individuals!with!confirmed!SARSJCoVJ2!in!London,!UK,!to!identify!demographic!and!clinical! variables!that!may!influence!dynamics!of!antibody!responses.! ! Methods! ! Ethics! Development!of!the!SARSJCoVJ2!IgG!ELISA!assay!is!published!elsewhere! (https://www.medrxiv.org/content/10. 1101/2020.04.29.20082099v1 ).!Anonymized!excess! diagnostic!material!(EDM)!from!patients!with!SARSJCoVJ2!infection!confirmed!by!RTJPCR! were!used!to!evaluate!antibody!dynamics!in!these!individuals.!The!study!is!sponsored!by!St! George's!Hospital!NHS!Trust!Foundation!and!has!Institutional!Review!Board!ethical! approval!(DARTS!study!J!IRAS!project!ID:!282104o!REC!reference:!20/SC/0171 Table! 2)!with!a! median!(IQR)!age!of!64!(52J77)!years,!57%!were!male,!and!most!(73%)!had!one!or!more!coJ morbidities.!Nineteen!percent!(34/177)!were!defined!as!asymptomatic!patients!and!did!not! report!respiratory!symptoms!on!admission.!They!were!diagnosed!with!COVIDJ19!when! investigated!for!other!medical!conditions.!Among!the!143!symptomatic!patients,!the!time! from!symptoms!initiation!to!testing!was!a!median!(IQR)!of!6!(3J9)!days.!Ninety!four!percent! (166/177)!were!hospitalized,!the!remainder!were!7!staff!and!4!outpatientso!25%!(44/177)! died!(median!(IQR)!time!to!death!was!19.1!(14.8J24.8!days)),!61%!(108/177)!were! discharged!(median!(IQR!)!length!of!stay!19.3!(10.6J31.1!days)),!and!8%!(14/177)!were!in! hospital!when!the!study!ended.!36%!(63/177)!patients!needed!intensive!care.! ! Figure! 1a!summarises!normalised!optical!density!values!(NOD)!from!the!ELISA,!proportional! to!specific!IgG!antibodies!of!patients!by!time!after!diagnosis.!8.5%!(95%CI!5.2%!J!13.5%o! 15/177)!did!not!seroconvert!during!the!entire!follow!up!period,!7.3%!(95%CI!4.3%!J!12.1%o! 13/177!seroconverted!after!enrolment!and!84%!(95%CI!78%!J!89%o!149/177)!had!already! seroconverted!at!the!time!of!the!first!serological!test.!Twenty!six!percent!(4/15)!of!the!nonJ seroconverters!were!followed!beyond!20!days,!suggesting!that!2J7%!of!patients!may!not! develop!detectable!IgG!antibody!responses!to!SARSJCoVJ2!for!weeks!following!infection.!! ! Figures!1b!and!1c!present!NOD!IgG!values!after!a!positive!RTJPCR!test!and!after!symptom! onset!respectively.!The!difference!in!the!estimated!time!for!NOD!values!to!plateau!from!RTJ PCR!(~12!dayso!Figure!1b)!and!after!onset!of!symptoms!(~19!dayso!Figure!1c)!is!~7!days! and!is!consistent!with!the!median!time!of!6!days!between!symptoms!and!RTJPCR!testing.! Following!seroconversion,!mean!NOD!values!remained!stable!over!the!time!of!study!(up!to! 2!months!after!onset!of!symptoms).! . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 9, 2020. . https://doi.org/10.1101/2020.06.07.20124636 doi: medRxiv preprint ! 5! ! We!next!assessed!whether!if!the!rate!of!seroconversion!was!higher!in!participants!≤!70!y! and!>!70!y,!by!sex,!or!the!presence!of!respiratory!symptoms.!None!of!these!variables! discernably!influenced!seroconversion!rates!(Figure!2aJc).! !! NOD!IgG!levels!were!not!influenced!by!sex!or!presence!or!absence!of!respiratory!symptoms! (Supplementary!Figures!2a!and!b) .!!NonJwhite!ethnicity!was!associated!with!higher!NOD! levels!than!being!white!(mean!values!1.06!vs!0.85!respectivelyo!p=!0.035o!unpaired! Student's!tJtesto!Supplementary! Figure!2c ).!! ! Seroconverters!(Figure!1a)!were!older!than!nonJseroconverters!(median!age!65.5!vs!41! yearso!Mann!Whitney!test!p!=!0.0033)!and!were!more!likely!to!have!one!or!more!coJ morbidities!(124/130!vs!38/47o!p!=!0.0045o!Fisher's!exact!test).!Hypertension!was!associated! with!a!higher!probability!of!seroconversion!(74/75!hypertensives!seroconverted!vs!88/102! nonJhypertensiveso!p!=!0.0025o!Fisher's!exact!test).!Body!mass!index!(BMI)!was!higher! among!the!group!who!seroconverted!(25.7!vs!21.2o!p!=!0.034).! ! CJreactive!protein!(CRP)!is!measured!routinely!in!patients!with!COVIDJ19!unlike!other! markers!of!inflammation,!and!rising!CRP!values!are!poor!prognostic!indicators!that!are! associated!with!cytokine!release!syndrome,!if!other!causes!are!excluded 6,7 .!CRP!values!on! admission!were!significantly!higher!in!patients!with!respiratory!symptoms!compared!with! those!without!(Figure!3a).!Patients!with!poor!outcomes!(death!or!admission!to!ITU)!had! higher!CRP!values!than!patients!with!good!outcomes!(Figure!3b).!Interestingly,!patients!who! did!not!seroconvert!had!lower!CRP!values!than!seroconverters!(Figure!3c).!The!CRP! differences!by!outcomes!and!seroconversion!were!more!marked!when!the!peak!CRP!values! were!analysed!(Figure!3o!right!hand!panel).!Other!inflammatory!markers,!such!as!peak!DJ dimer,!fibrinogen!or!ferritin!were!also!higher!in!symptomatic!compared!with!asymptomatic! patients,!but!were!available!for!fewer!patients!( Higher!NOD!values!were!associated!with!ethnicity!(being!nonJwhite),!probability!of! admission!to!hospital,!and!higher!peak!values!for!markers!of!inflammation!such!as!CRP.! Higher!antibody!titres!are!associated!with!clinical!severity 4 .!! CRP!is!a!sensitive!marker!of!elevated!proJinflammatory!cytokines!like!InterleukinJ6!that!are! hypothesised!to!play!a!central!role!in!the!cytokine!release!syndrome!that!presages!a!high! mortality 7 .!Interventions!that!target!the!proinflammatory!cascade!such!as!the!antiJinterleukinJ 6!receptor!antibody,!tocilizumab,!may!reverse!disease!progression!and!reduce!mortality 11,12 ! and!are!being!studied!urgently!in!randomised!clinical!trials!(20!trials!listed!currently).!A!small! proportion!of!individuals!did!not!seroconvert!even!by!20!days!after!a!positive!RTJPCR!test! for!SARSJCoV2.!It!may!be!that!these!patients!never!seroconvert!or!they!may!have!immune! responses!confined!to!other!antigens!or!mediated!through!T!cells.!Another!likely!explanation! is!that!relatively!mild!infections!may!have!been!restricted!to!the!mucosal!cells!of!the! respiratory!tract,!where!antibody!responses!are!dominated!by!the!secretory!immune!system! and!little,!if!any,!IgG!antibody!production!in!the!systemic!immune!compartment.! The!association!of!higher!NOD!ELISA!values!with!elevated!CRP!could!be!interpreted!in! several!ways.!It!is!possible!that!antibody!responses!are!working!in!concert!with!the!cytokine! response!syndrome!and!are!associated!with!more!severe!disease!and!risk!of!death!through! this!mechanism.!Alternatively,!elevated!CRP!values!may!indicate!a!more!marked!innate! response!to!infection!in!those!at!risk!of!severe!disease!and!death.!This!heightened!innate! response!may!itself!be!associated!with!a!higher!viral!load!(perhaps!through!enhanced! replication!mechanisms)!and!interactions!with!genes!that!influence!innate!inflammatory! pathways.!A!higher!viral!load!would!be!predicted!to!give!rise!to!higher!NOD!ELISA!values!for! antibodies!in!the!acquired!immune!response!pathways.!The!potential!therapeutic!benefits!of! passive!antibody!transfer!studies!(in!small!trials 13 )!suggest!that!the!latter!hypothesis!is!more! likely 14 .!Higher!antibody!responses!are!also!seen!with!higher!doses!of!nonJreplicating!Ad5! vectored!SARSJCoVJ2!vaccine 15 .! Limitations!of!RTJPCR!testing!include!difficulties!with!sampling,!with!different!sample!types! and!techniques!yielding!variable!results,!and!diminishing!diagnostic!yield!after!peak!viral! loads!that!usually!occur!at!the!time!of!symptoms 10,16 .!There!may!also!be!biological!false! positives!associated!with!persistence!of!viral!nucleic!acid!but!no!longer!infective!virus!weeks! after!infection,!or!in!sample!handling.!Serological!testing,!and!the!ability!to!detect!viral! antigens,!may!increase!diagnostic!accuracy!for!COVIDJ19!and!our!findings!support!early! studies!suggesting!that!these!diagnostic!modalities!should!be!combined,!particularly!when! RTJPCR!results!are!negative!but!patients'!symptoms!resemble!those!of!COVIDJ19 8 .!Late! presentation!to!secondary!care!is!common!and!may!be!part!of!containment!strategies!that! encourage!isolation.! One!limitation!of!our!study!is!that!it!is!based!mainly!on!hospitalised!patients!of!whom!1!in!5! did!not!present!with!symptoms!of!COVIDJ19.!Further!studies!are!needed!to!document! antibody!dynamics!of!patients!with!less!severe!infections,!such!as!in!healthcare!workers!in! eastern!France 17 !and!those!who!may!have!been!missed!because!they!already!had!low!viral! loads!at!the!time!of!consultation.!However,!our!findings!will!complement!the!large!crossJ sectional!and!longitudinal!serological!surveys!being!implemented!as!high!quality!tests! become!more!widely!available.!ELISA!NOD!values!were!within!a!limited!dynamic!range! (dilution!studies!could!not!be!carried!out!because!sample!volumes!or!resources!were! limiting)!but,!nevertheless,!were!found!to!be!related!to!clinically!relevant!features!of!COVIDJ 19.!Prospective!studies!are!assessing!the!relationships!between!viral!loads!(assessed!by! RTJPCR)!and!serological!responses!in!patients.!Regular!and!longerJterm!serological!assays! . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 9, 2020. . https://doi.org/10.1101/2020.06.07.20124636 doi: medRxiv preprint ! 7! will!also!be!needed!to!monitor!the!duration!and!contribution!of!humoral!responses!to! protection!from!SARSJCoVJ2.! ! !!!! We!are!greatly!indebted!to!the!National!Association!of!Blood!Bikes!(NABB)!for!their! unwavering!assistance!in!transporting!samples,!prototypes,!and!validated!devices!between! Liverpool,!Bedford,!and!London.!Without!the!NABB,!we!could!not!have!delivered!two!CE! marked!products!in!8!weeks!from!project!launch.!We!also!thank!the!tireless!laboratory!staff! of!SWLP!and!informatics!team!particularly!James!Lawrence. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 9, 2020. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 9, 2020. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 9, 2020. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 9, 2020. . https: //doi.org/10.1101 //doi.org/10. /2020 swab!for!!seroconverted!(grey!crosses),!seroconverting!(blue!circles)!and!nonJ seroconverting!patients!(red!circles).!1b!Mean!(±SEM)!NOD!values!(≥!3!per!time!pointo!n!=! 48)!by!days!after!first!PCR!positive!swab!for!those!who!seroconverted.!A!4Jparameter! sigmoidal!unconstrained!model!was!fitted!(r 2 !=!0.45).!1c!Mean!(±SEM)!NOD!values!(≥!3!per! time!pointo!n!=!45)!by!days!after!first!symptoms!for!those!who!seroconverted.!A!4Jparameter! sigmoidal!unconstrained!model!was!fitted!(r 2 !=!0.63).! ! Figure! 2!Cumulative!frequency!plots!for!seroconversion!Probability!of!seroconversion!is! described!in!days!after!an!RTJPCR!positive!swab.!2a!Patients!presenting!with!(filled! squares)!or!without!(filled!circles)!respiratory!symptoms!are!shown,!with!the!last!available! seronegative!sample!for!a!patient!indicated!by!symbols!and!subsequently!right!censored!2b! Patients!aged!≥!70!y!(filled!squares)!or!<70!y!(filled!circles)!are!shown,!with!the!last!available! seronegative!sample!for!a!patient!indicated!by!symbols!and!subsequently!right!censored!2c! Patients!male!(filled!squares)!or!female!(filled!circles)!are!shown,!with!the!last!available! seronegative!sample!for!a!patient!indicated!by!symbols!and!subsequently!right!censored.!! ! Figure! 3!Relationships!between!CRP!values,!symptoms,!outcomes,!and!NOD!values! CRP!levels!(left!hand!panelo!medians!and!interquartile!ranges)!at!the!time!of!the!RTJPCR! diagnosis!are!shown!for!3a!symptomatic!(open!circles)!and!asymptomatic!(filled!circles)! patientso!3b!for!patients!admitted!to!intensive!care!and/or!who!died!(open!circles)!and!those! who!were!not!(closed!circles)o!3c!those!who!seroconverted!(open!circles)!and!those!who!did! not!(closed!circles).!3dJf!Peak!CRP!levels!corresponding!to!3aJc!are!shown!(right!hand! panelo!medians!and!interquartile!ranges).!Statistical!significance!calculated!using!MannJ Whitney!test!for!CRP!values!(mg/L).!3a,!97!(n!=!113)!vs!56!(n!=!21),!p!=!0.0008o!3b,!107!(n!=! 62)!vs!75.5!(n!=!72),!p!=!0.011o!3c,!93!(n!=!123)!vs!28!(n!=!11),!p!=!0.04o!3d,!median!values! respectively!of!255!(n!=!142)!compared!with!104!(n!=!34)!respectivelyo!p!<0.0001o!3e,!322!(n! =!80)!vs.!137.5!(n!=!96),!p!<0.0001o!3f,!224!(n!=!161)!vs!101!(n!=!15),!p!=!0.025.! ! ! ! ! ! . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 9, 2020. . https://doi.org/10.1101/2020.06.07.20124636 doi: medRxiv preprint CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 9, 2020. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 9, 2020. . https://doi.org/10.1101/2020.06.07.20124636 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 9, 2020. . https://doi.org/10.1101/2020.06.07.20124636 doi: medRxiv preprint (an!early!generation!assay!used!NP,!S1!and!S2! antigens!and!the!finalized!version!used!only!NP!and!S2!antigens,!with!S1!being!removed).! Six!wells!contained!controls:!negative!(diluent!solution Indicator/substrate!solution!(3,3′,5,5′Jtetramethylbenzidine,!TMB,!with!H 2 Ethnicity!data!are!routinely!collected!by!the!National!Health!Service!and!categorised!based! on!the!2001!UK!Census!classification.!*Height!data!unavailable!for!13!patients